miR-130a

rna

miR-130a modulates inflammatory signaling in atherosclerotic plaque.

Pathway placement

Cascade stepPlaque inflammation

Confidencemedium

RationalemiR-130a regulates inflammatory pathway activation in ACS.

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-30.5

Confounder panel (Type-II drivers)

No confounder evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Whole blood or cell-free plasma

Collection tube

PAXgene/Tempus RNA tube · K2/K3-EDTA (lavender-top)

Method / principle

RT-qPCR (TaqMan) or small-RNA sequencing

Reagent / substrate

Target-specific primers/probe; reverse transcriptase (miRNA: stem-loop RT primer)

Platform

qPCR instrument / NGS

Turnaround · availability

Research / send-out · Research (few LDTs)